The evolving landscape of brain metastasis: volume II.
AuteursValiente M, Anders C, Boire A, Izar B, Kotecki N, Malladi S, Massagué J, Moss NS, Neman J, Preusser M, Schagen S, Siegel PM, Tawbi H, Venkataramani V, Winkler F, Zadeh G, Joyce JA
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.
AuteursWildiers H, Adam V, O'Reilly S, Van Cauwenberge J, Arahmani A, Arteaga CL, Bedard PL, Bliss J, Boussis P, Brain E, Buyse M, Caballero C, Cameron D, Cardoso F, Carrasco E, Casas A, Chua B, Curigliano G, DeMichele A, Esserman L, Floris G, Goetz MP, Goulioti T, Haibe-Kains B, Hodgdon C, Ignatiadis M, Kok M, Lacombe D, Linderholm B, Loi S, Lord CJ, MacKenzie M, Maues J, Meheus L, Needham J, Neven P, Parsons H, Piccart M, Pusztai L, Razis E, Saji S, Schumacher-Wulf E, Sonke GS, Spanic T, Tannock IF, Tutt A, Urruticoechea A, van 't Veer L, Vaz-Luis I, Werutsky G, Yee D, Zaman K, Desmedt C
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial.
AuteursJhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Watanabe J, Lim E, Huang J, Qingyuan Z, Llombart-Cussac A, Huang C, Desai B, Limay Y, Wang XA, Cao S, Bidard FC
Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.
AuteursBhave M, Jhaveri KL, Kaufman PA, Aftimos P, Lombard J, Giridhar KV, Im SA, Ma CX, Lee KT, Kim SB, Sohn J, Li Y, Yuen E, Estrem ST, Nguyen B, Makena MR, Ismail-Khan R, Beeram M
Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib - final 6-year results from a Belgian registry.
AuteursDevos T, Deeren D, Theunissen K, Selleslag D, Bailly B, Havelange V, Lewalle P, Meers S, Benghiat FS, Gadisseur A, Granacher N, Vanstraelen G, Vellemans H, Becker A, Janssen M, Vrelust I, Lejeune M, Van de Velde A, Triffet A, Beck M, Sebti H, Mazure D
